Company: DNLI
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001714899-25-000105
Chunk: 410

Company: Denali Therapeutics Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 410
---
 to the Company’s single operating segment for the three months ended March 31, 2025 and 2024 (in thousands):Therapeutics SegmentThree Months Ended March 31,20252024ExpensesExternal research and development expenses - TV programs, including cost sharing$41,987 $35,684 External research and development expenses - small molecule programs, including cost sharing8,854 13,121 Other research and development expenses25,117 15,881 Personnel related research and development expenses40,269 42,330 Total research and development expenses116,227 107,016 Personnel related general and administrative expenses18,738 19,085 Other general and administrative expenses10,615 6,151 Total general and administrative expenses29,353 25,236 Segment operating expenses145,580 132,252 Segment gain from divestiture of small molecule programs— (14,537)Segment loss from operations(145,580)(117,715)Segment interest and other income, net12,610 15,913 Segment loss before income taxes$(132,970)$(101,802)

There is no difference between the segment loss before income taxes and total consolidated loss before income taxes for the three months ended March 31, 2025 and 2024. 

21

ITEM 2.     MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q. This discussion and analysis and other parts of this report contain forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future financial performance that involve risks, uncertainties, and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts, and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the section titled “Risk Factors” included in this Quarterly Report on Form 10-Q.

Forward-looking statements include, but are not limited to, statements about:

•the progress, success, cost, and timing of our development activities, preclinical studies, and clinical trials, and in particular the development of our blood-brain barrier (“BBB”) platform, programs, and